Diclofenac sodium 75mg gastro-resistant / Misoprostol 200microgram tablets
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Diclofenac sodium + Misoprostol
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
11 branded products available
MHRA licensed products
View all licensed products for Diclofenac sodium + Misoprostol on the MHRA register
Arthrotec 75 gastro-resistant tablets
Diclofenac sodium 75mg gastro-resistant / Misoprostol 200microgram tablets
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
100 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 8 · Randomised trials: 11 · 1999–2025
Showing the 50 most relevant studies, sorted by most relevant.
R. Petrella, M. D. DiSilvestro, C. Hildebrand
Archives of internal medicine, 2002
Salah N, Maged AM, Mahmoud SI, et al.
2024
- Oxytocics
- Misoprostol
- Hysteroscopy
Hetao Huang, Ming-hui Luo, Hao-Dong Liang, et al.
Pain Medicine: The Official Journal of the American Academy of Pain Medicine, 2020
Huixin Shao, Xu Zhao, Yanbin Wang, et al.
Applied Catalysis B-environmental, 2017
Nafisa Gull, S. Khan, O. M. Butt, et al.
International journal of biological macromolecules, 2020
Vatankhah M, Zargar N, Naseri M, et al.
2023
- Pulpitis
- Ibuprofen
- Molar
Sowjanyaa Jenarthanan, C. Subbarao
Journal of Conservative Dentistry : JCD, 2018
Hafsa Rauf, Samia Malik, Ayesha Rehman
Indus Journal of Bioscience Research, 2025
Background: Postoperative pain after cesarean section remains a frequent clinical concern and may delay mobilization and recovery. Nonsteroidal anti-inflammatory drugs such as diclofenac sodium are commonly used, but the optimal route of administration for effective analgesia and reduced need for rescue medication remains debated. Aim: To compare the effectiveness of per-rectal diclofenac sodium versus intramuscular diclofenac sodium for postoperative analgesia after cesarean section. Materials and Methods: A randomized controlled trial was conducted in the Department of Obstetrics and Gynecology, National Hospital Lahore, from November 2024 to April 2025. A total of 274 primigravida women (137 per group), aged 18 to 35 years, with singleton pregnancies and ASA physical status I or II undergoing cesarean section under spinal anesthesia were enrolled through non-probability consecutive sampling. Group A received intramuscular diclofenac sodium 75 mg twice daily for 24 hours, while Group B received per-rectal diclofenac suppository 100 mg twice daily. Primary outcome was the requirement of rescue analgesia within 24 hours. Secondary outcomes included Visual Analogue Score at 24 hours and time to rescue analgesia. Data were analyzed using chi-square and independent sample t-tests. Results: Mean maternal age was 26.42 ± 4.18 years in Group A and 25.87 ± 4.32 years in Group B (p = 0.31). Mean gestational age was 38.16 ± 1.52 versus 38.34 ± 1.48 weeks (p = 0.34), and mean body mass index was 27.63 ± 3.41 versus 27.28 ± 3.56 kg/m² (p = 0.43). Rescue analgesia was required in 79 participants (57.66%) in Group A and 58 participants (42.34%) in Group B (p = 0.011). Mean 24-hour VAS score was 4.53 ± 1.82 in Group A and 3.76 ± 1.96 in Group B (p = 0.001). Time to rescue analgesia was 3.87 ± 2.46 hours versus 4.52 ± 2.71 hours (p = 0.14). Conclusion: Per-rectal diclofenac sodium achieved better postoperative pain control and reduced reliance on rescue analgesia compared to intramuscular diclofenac sodium after cesarean section.
Abstract licence: CC BY 4.0
Derry S, Wiffen PJ, Moore RA
2015
- Diclofenac
- Anti-Inflammatory Agents, Non-Steroidal
- Cyclooxygenase Inhibitors
Thiago César Lima, Elizabete Bagordakis, S. Falci, et al.
Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2018
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.